Dallas, TX: ReportsandReports announce UCB S.A.: PharmaVitae Profile Market Research Report in its Store.
Browse complete Report at: http://www.reportsandreports.com/reports/8511-ucb-sa-pharmavitae-profile.html
This analysis examines the historical and forecast performance for UCB in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
• Benchmark UCB’s performance against key rivals in the ethical pharmaceutical sector
• Assess how M&A has shaped UCB into a next generation bio-pharmaceutical player
• Assess UCB’s market leading position in the epilepsy treatment segment and the use of life cycle management in a bid to retain this status
• Table Of Contents
• ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
• Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 3
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
• Chapter 2 Executive summary 5
• Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Financial performance, 2002-14 7
UCB: PharmaVitae forecasts at a glance 8
Strategic insight 9
Epilepsy launches central to overcoming Keppra generics 9
Vimpat and Rikelta in line to replace Keppra as UCB’s next-generation AED medications 9
Biopharmaceutical business model yet to deliver growth 11
SWOT analysis 12
• Table of Contents 13
• Table of figures 15
• Chapter 3 Quarterly news update 16
• Product developments 16
Deals and alliances 18
Product deals 18
Company announcements 19
• Chapter 4 Company introduction 20
• Key findings 20
Background 21
Key corporate developments 21
M&A history 22
Celltech 22
Schwarz Pharma 23
• Chapter 5 Company sales 24
• Key findings 24
Prescription pharmaceutical sales and growth rate analysis, 2002-14 25
Product analysis 26
Product analysis, 2002-08 27
Product analysis, 2008-14 30
Therapy area analysis 33
Geographic analysis 35
Launch/core/expiry analysis 37
Explanation of launch/core/expiry analysis 37
Launch analysis, 2008-14 38
Core analysis, 2008-14 39
Expiry analysis, 2008-14 40
Generics analysis, 2008-14 41
Launch/core/expiry configuration, 2008-14 42
Molecule type analysis 43
Externalization analysis 45
• Chapter 6 Company financials 47
• Key findings 47
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 48
Operating costs and profit analysis 49
Operating costs and profit analysis, 2002-08 50
Operating cost ratio and profit margin analysis, 2002-08 51
Operating cost ratio and profit margin analysis, 2008-14 52
Operating costs and profit analysis, 2008-14 53
• Chapter 7 Key products and competitors 54
• Key findings 54
Overview 55
Central nervous system 56
Keppra/Keppra XR 56
Overview 57
Sales forecast 58
Gold standard anti-epileptic drug 58
Launch of Keppra XR in September 2008 represents a clear lifecycle management strategy 59
Generics will erode a significant portion of the Keppra franchise’s market share 60
Japan market penetration offers franchise some growth opportunity 60
Rikelta 61
Overview 62
Sales forecast 63
Next-generation version of Keppra currently in phase III trials 63
Datamonitor expects brivaracetam’s target population to be treatment-refractory epilepsy patients 64
Neupro 65
Overview 66
Sales forecast 67
Novel Parkinson’s formulation 67
Product recall in the US expected to slow uptake 67
Improved compliance and symptom control set to drive uptake 68
Vimpat 70
Overview 71
Sales forecast 72
Vimpat is the newest member of UCB’s antiepileptic franchise 72
Approval as an adjunctive epilepsy treatment set to boost UCB offering 73
Neuropathic pain use rejected by FDA 73
Cannibalization of sales by brivaracetam represents a key threat to Vimpat 74
Immunology & inflammation 75
Cimzia 75
Overview 76
Sales forecast 77
UCB’s novel anti-TNF mAb finally gets green light 77
Non-responder patient population and pricing offer key route to uptake 78
Cimzia is back in Phase III for Crohn’s disease in the EU – Datamonitor updated its forecast to reflect impact of a Cimzia launch 78
• Chapter 8 Appendix 80
• R&D pipeline 80
References 81
Abbreviations 81
Exchange rates 83
About Datamonitor 84
About Datamonitor Healthcare 84
Datamonitor consulting 84
Disclaimer 86
• List of Tables
• Table 1: UCB – PharmaVitae forecasts at a glance 8
Table 2: UCB key product developments, 2009 16
Table 3: UCB deals and alliances, 2009 18
Table 4: UCB company announcements, 2009 19
Table 5: UCB product portfolio overview ($m), 2002-08 27
Table 6: UCB product portfolio overview ($m), 2008-14 30
Table 7: UCB prescription pharmaceutical sales by therapy area ($m), 2008-14 34
Table 8: UCB prescription pharmaceutical sales by geographic region ($m), 2008-14 36
Table 9: UCB launch portfolio overview ($m), 2008-14 38
Table 10: UCB core portfolio overview ($m), 2008-14 39
Table 11: UCB expiry portfolio overview ($m), 2008-14 40
Table 12: UCB generics portfolio overview ($m), 2008-14 41
Table 13: UCB prescription pharmaceutical sales by molecule type ($m), 2008-14 44
Table 14: UCB prescription pharmaceutical sales by source ($m), 2008-14 46
Table 15: Total UCB sales by business unit ($m), 2002-08 48
Table 16: UCB operating revenue/cost analysis ($m), 2002-08 50
Table 17: UCB operating cost ratio analysis (% of total revenues), 2002-08 51
Table 18: UCB operating cost ratio analysis (% of total revenues), 2008-14 52
Table 19: UCB operating revenue/cost analysis ($m), 2008-14 53
Table 20: Key products overview 55
Table 21: Keppra/Keppra XR: overview 57
Table 22: Keppra/Keppra XR: sales forecast ($m), 2008-14 58
Table 23: Rikelta: overview 62
Table 24: Rikelta: sales forecast ($m), 2008-14 63
Table 25: Neupro: overview 66
Table 26: Neupro: sales forecast ($m), 2008-14 67
Table 27: Vimpat: overview 71
Table 28: Vimpat: sales forecast ($m), 2008-14 72
Table 29: Cimzia: overview 76
Table 30: Cimzia: sales forecast ($m), 2008-14 77
Table 31: UCB’s R&D pipeline (Phase I-registration) 80
Table 32: Exchange rates, 2009 83
ABBREVIATIONS
Browse all : Healthcare Market Research Reports
http://www.reportsandreports.com/cat/healthcare-market-research.html
Browse all : Datamonitor Market Research Reports
http://www.reportsandreports.com/Publisher/datamonitor-market-research.html-market-research.html
Browse all Newly Published Market Research Reports
http://www.reportsandreports.com/LatestReport.aspx
Original Source : PharmaV itae Market
http://www.reportsandreports.com/reports/8511-ucb-sa-pharmavitae-profile.html
Buy Now : Market Research Report
http://www.reportsandreports.com/
Related Reports:
Browse all : UCB S.A. – SWOT Analysis
at : http://www.reportsandreports.com/reports/2122-ucb-sa-swot-analysis.html
Browse all :Solvay S.A.: PharmaVitae Profile
at : http://www.reportsandreports.com/reports/8513-solvay-sa-pharmavitae-profile.html
Browse all :UCB Japan Co., Ltd.-Detailed Product Pipeline
at : http://www.reportsandreports.com/reports/30998-ucb-japan-co-ltd-detailed-product- pipeline.html
Browse all :UCB S.A.-Detailed Product Pipeline
at : http://www.reportsandreports.com/reports/30999-ucb-sa-detailed-product-pipeline.html
Browse all : UCB Japan Co., Ltd.-Company Report
at : http://www.reportsandreports.com/reports/6485-ucb-japan-co-ltd-company-report.html
About Us:
Reports and Reports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Website: http://www.reportsandreports.com/
Blog: http://reportsnreports.wordpress.com/
Blog: http://reportsandreports.blogspot.com/
